Ultragenyx Pharmaceutical Inc.
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypopā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$26.30
Price+0.69%
$0.18
1Y
Price
Market Cap
$2.590b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-118.4%
EBITDA Margin-136.0%
Net Profit Margin-145.6%
Free Cash Flow Margin-118.4%
EBITDA Margin-136.0%
Net Profit Margin-145.6%
Free Cash Flow MarginRevenue
$669.429m
-0.5%
1y CAGR+16.2%
3y CAGR+17.0%
5y CAGREarnings
-$609.364m
-6.0%
1y CAGR-0.3%
3y CAGR+3.4%
5y CAGREPS
-$6.11
-4.8%
1y CAGR+8.8%
3y CAGR+11.2%
5y CAGRBook Value
-$229m
$1.296b
Assets$1.525b
Liabilities$1.200b
DebtDebt to Assets
92.6%
-2.3x
Debt to EBITDAFree Cash Flow
-$487.201m
-3.2%
1y CAGR+1.3%
3y CAGR+1.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company